2021
Renal Denervation for Hypertension A Systematic Review and Meta-Analysis of Randomized, Blinded, Placebo-Controlled Trials
Ahmad Y, Francis D, Bhatt D, Howard J. Renal Denervation for Hypertension A Systematic Review and Meta-Analysis of Randomized, Blinded, Placebo-Controlled Trials. JACC Cardiovascular Interventions 2021, 14: 2614-2624. PMID: 34743900, DOI: 10.1016/j.jcin.2021.09.020.Peer-Reviewed Original ResearchConceptsPlacebo-controlled trialRenal denervationAntihypertensive medicationsBlood pressureMeta-analysisCatheter-based renal sympathetic denervationEffect of renal denervationRandomized placebo-controlled trialDrug-resistant hypertensionConcomitant antihypertensive medicationOffice blood pressureRenal sympathetic denervationAmbulatory systolic blood pressureRandom-effects meta-analysisSystolic blood pressureEffects of denervationAntihypertensive medication useMagnitude of benefitOffice systolicPlacebo-controlledEfficacy outcomesSympathetic denervationAntihypertensive agentsAmbulatory systolicEligible trialsRandomized Blinded Placebo-Controlled Trials of Renal Sympathetic Denervation for Hypertension: A Meta-Analysis
Ahmad Y, Kane C, Arnold AD, Cook CM, Keene D, Shun-Shin M, Cole G, Al-Lamee R, Francis DP, Howard JP. Randomized Blinded Placebo-Controlled Trials of Renal Sympathetic Denervation for Hypertension: A Meta-Analysis. Cardiovascular Revascularization Medicine 2021, 34: 112-118. PMID: 33551282, PMCID: PMC8813172, DOI: 10.1016/j.carrev.2021.01.031.Peer-Reviewed Original ResearchConceptsRenal denervationRelative risk reductionBlood pressureCatheter-based renal denervationMajor adverse cardiac eventsPlacebo-controlled trial dataAmbulatory diastolic blood pressureAmbulatory systolic blood pressurePlacebo-controlled randomized trialSystolic blood pressure changesOffice diastolic pressureRandomized blinded placeboAdverse cardiac eventsOffice blood pressurePlacebo-controlled trialPrimary efficacy outcomeDiastolic blood pressureRenal sympathetic denervationSystolic blood pressureBlood pressure changesRisk reductionCause mortalityEfficacy outcomesSympathetic denervationAdverse events
2013
Preventing Stroke and Systemic Embolism in Renal Patients with Atrial Fibrillation: Focus on Anticoagulation
Ahmad Y, Lip GY. Preventing Stroke and Systemic Embolism in Renal Patients with Atrial Fibrillation: Focus on Anticoagulation. Contributions To Nephrology 2013, 179: 81-91. PMID: 23652451, DOI: 10.1159/000346726.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnticoagulantsAtrial FibrillationBenzimidazolesBeta-AlanineClinical Trials as TopicComorbidityDabigatranDisease ManagementEmbolismFemaleFibrinolytic AgentsHemorrhageHumansHypertensionIntracranial EmbolismMaleMorpholinesPatient SelectionPyrazolesPyridonesRenal Insufficiency, ChronicRiskRisk FactorsRivaroxabanSeverity of Illness IndexStrokeThiophenesThrombophiliaWarfarinConceptsSevere renal impairmentAtrial fibrillationRisk factorsGeneral populationRenal impairmentRenal diseaseRenal patientsAbsence of AFLarge randomised control trialBenefits of warfarinNew oral anticoagulantsChronic kidney diseaseCohort of patientsRisk of strokeRandomised control trialEctopic vascular calcificationMajority of trialsUnique management challengesAF independentSystemic embolismOral anticoagulantsRenal insufficiencyStroke preventionThromboembolic riskStroke risk